EFFECTIVENESS OF COMBINATION TREATMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Abstract
About the Authors
A. V. Bogachev-ProkofyevRussian Federation
S. I. Zheleznev
Russian Federation
M. S. Fomenko
Russian Federation
A. N. Pivkin
Russian Federation
R. M. Sharifulin
Russian Federation
O. Yu. Malakhova
Russian Federation
A. M. Karaskov
Russian Federation
References
1. Elliott P, Andersson B, Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. // Eur Heart J 2008;29:270-276.
2. Elliott PM., Anastasakis A, Borger MA. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). // European Heart Journal 2014; August 29: 1-55.
3. Olivotto I, Cecchi F, Casey SA. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. // Circul ation 2001; 104: 2517 - 2524.
4. Maron BJ, Olivotto I, Bellone P. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. // J Am Coll Cardiol 2002; 39(2): 301 - 307.
5. Siontis KC., Geske JB., Ong K. et al. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High-Risk Population. // J Am Heart Ass 2014; 3: 1 - 8.
6. Maron BJ, Casey S, Poliac L. et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. //JAMA 1999; 281(7): 650 -655.
7. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation. // J Am Coll Cardiol 2014; 63: e57- e185.
8. Sherrid MV, Barac I, McKenna WJ. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. // J Am Coll Cardiol 2005; 45(8): 1251-1258.
9. Cappato R, Calkins, H, Chen SA. et al. Updated world wide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. // Circ Arrhythm Electrophysiol 2010; 3(1): 32-38.
10. Di Donna P, Olivotto I, Delcre SD. et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. // Europace 2010; 12(3): 347-355.
11. Bunch TJ, Munger TM, Friedman PA. et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. // J Cardiovasc Electrophysiol 2008; 19(10): 1009 -1014.
12. Gaita F, Di Donna P, Olivotto I. et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007; 99(11): 1575-1581.
13. Kilicaslan F, Verma A, Saad E. et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. // Heart Rhythm 2006; 3(3): 275-280.
14. Chen MS, McCarthy PM, Lever HM. et al. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. // Am J Cardiol 2004; 93: 373 -375.
15. User’s Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. - Медиа Сфера. Перевод с англ., М. 2003. 376 с.
16. Messmer BJ. Extended Myectomy for Hypertrophic Obstructive Cardiomyopathy. // Ann Thorac Surg 1994; 58: 575-577.
17. Gorbatikh Yu.N., Len’ko E.V., Ivanov A.A. et al. // Cardiology & cardiovascular surgery. 2012. №5. С. 53-59 (Kardiol serdecno-sosud hir 2012; 5: 53-59).
18. Damiano R, Baileyb M. The Cox-Maze IV procedure for lone atrial fibrillation. // Multimedia Manual of Cardiothoracic Surgery 2007. 0-7.
19. Benussi S, Galanti A, Zerbi V. et al. Electrophysiologic efficacy of irrigated bipolar radiofrequency in the clinical setting. // The Journal of Thoracic and Cardiovascular Surgery 2010; 139(5): 1131 - 1136.
20. Cox JL, Ad N, Palazzo T, Fitzpatrick S. et al. Current status of the Maze procedure for the treatment of atrial fibrillation. // Semin Thorac Cardiovasc Surg 2000; 12: 15-19.
21. Henn MC, Lancaster TS, Miller JR. et al. Late outcomes after the Cox maze IV procedure for atrial fibrillation. // J Thorac Cardiovasc Surg. 2015 Nov;150(5):1168-1178.
22. Bassiouny M, Lindsay B, Lever H. et al. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. // Heart Rhythm 2015; 0: 0-10.
23. Connelly JH, Clubb FJ, Vaughn W, Duncan M. Morphological changes in atrial appendages removed during the maze procedure: a comparison with autopsy controls. // Cardiovasc Pathol 2001; 10: 39 - 42.
24. Robertson JO, Cuculich PS, Saint LL. et al. Predictors and Risk of Pacemaker Implantation After the Cox - Maze IV Procedure. // Ann Thorac Surg 2013;95:2015-21.
25. Kobayashi J, Kosakai Y, Nakano K. et al. Improved success rate of the maze procedure in mitral valve disease by new criteria for patients’ selection. // European Journal of Cardio-thoracic Surgery 1998; 13: 247-252.
Review
For citations:
Bogachev-Prokofyev A.V., Zheleznev S.I., Fomenko M.S., Pivkin A.N., Sharifulin R.M., Malakhova O.Yu., Karaskov A.M. EFFECTIVENESS OF COMBINATION TREATMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY. Journal of Arrhythmology. 2016;(84):12-16. (In Russ.)